Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Etigilimab · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Etigilimab | DRUG | IV infusion of IV etigilimab every 2 weeks |
| Nivolumab | DRUG | IV infusion of nivolumab every 2 weeks |
Etigilimab is an investigational small molecule being studied for the treatment of solid tumors in adults, including locally advanced or metastatic tumors. It is currently in Phase 2 clinical development for these oncology indications.
Etigilimab is being developed by Mereo BioPharma Group plc, a biopharmaceutical company. The company's stock is traded under the ticker symbol MREO.
Etigilimab is in Phase 2 clinical development for the treatment of solid tumors in adults. It remains an investigational drug and has not been approved by regulatory authorities.
Etigilimab has been studied in a clinical trial with the identifier NCT04761198, titled 'A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors.' This trial, which combined Etigilimab with nivolumab, has been completed.
Etigilimab is a small molecule, but its specific molecular target has not been disclosed in available information. Therefore, its mechanism of action is not described here.